A New Frontier in B-Cell Autoimmune Therapy Antengene Corporation recently announced a significant milestone in its clinical development pipeline. The company has received clinical trial approval in Australia to initiate a Phase I study, known as the ATTRACT study, for their novel therapeutic candidate, ATG-201. Understanding ATG-201 ATG-201 is a CD19 x CD3 T-cell engager…